CoChat

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

Open access
Turner, N.C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., Fox, L., Goddard, K., Garcia-Murillas, I., Proszek, P., Hall, P., Harper-Wynne, C., Hickish, T., Kernaghan, S., Macpherson, I.R., Okines, A.F.C., Palmieri, C., Perry, S., Randle, K., Snowdon, C., Stobart, H., Wardley, A.M., Wheatley, D., Waters, S., Winter, M.C., Hubank, M., Allen, S.D., Bliss, J.M., S. Chan, Armstrong, A., Raja, F., Schmid, P., Tutt, A., Roux, R., Cleator, S. · 2023 · Annals of Oncology
Cited by 208

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Post-treatment detection of circulating tumour DNA (ctDNA) in early-stage triple-negative breast cancer (TNBC) patients predicts high risk of relapse. c-TRAK TN assessed the utility of prospective ctDNA surveillance in TNBC and the activity of pembrolizumab in patients with ctDNA detected [ctDNA positive (ctDNA+)]. PATIENTS AND METHODS: c-TRAK TN, a multicentre phase II trial, with integrated prospective ctDNA surveillance by digital PCR, enrolled patients with early-stage TNBC and residual disease following neoadjuvant chemotherapy, or stage II/III with adjuvant chemotherapy. ctDNA surveillance comprised three-monthly blood sampling to 12 months (18 months if samples were missed due to coronavirus disease), and ctDNA+ patients were randomised 2 : 1 to intervention : observation. ctDNA results were blinded unless patients were allocated to intervention, when staging scans were done and those free of recurrence were offered pembrolizumab. A protocol amendment (16 September 2020) closed the observation group; all subsequent ctDNA+ patients were allocated to intervention. Co-primary endpoints were (i) ctDNA detection rate and (ii) sustained ctDNA clearance rate on pembrolizumab (NCT03145961). RESULTS: Two hundred and eight patients registered between 30 January 2018 and 06 December 2019, 185 had tumour sequenced, 171 (92.4%) had trackable mutations, and 161 entered ctDNA surveillance. Rate of ctDNA detection by 12 months was 27.3% (44/161, 95% confidence interval 20.6% to 34.9%). Seven patients relapsed without prior ctDNA detection. Forty-five patients entered the therapeutic component (intervention n = 31; observation n = 14; one observation patient was re-allocated to intervention following protocol amendment). Of patients allocated to intervention, 72% (23/32) had metastases on staging at the time of ctDNA+, and 4 patients declined pembrolizumab. Of the five patients who commenced pembrolizumab, none achieved sustained ctDNA clearance. CONCLUSIONS: c-TRAK TN is the first prospective study to assess whether ctDNA assays have clinical utility in guiding therapy in TNBC. Patients had a high rate of metastatic disease on ctDNA detection. Findings have implications for future trial design, emphasising the importance of commencing ctDNA testing early, with more sensitive and/or frequent ctDNA testing regimes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2022.11.005

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 208

Metadata

Authors
Turner, N. C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., Fox, L., Goddard, K., Garcia-Murillas, I., Proszek, P., Hall, P., Harper-Wynne, C., Hickish, T., Kernaghan, S., Macpherson, I. R., Okines, A. F. C., Palmieri, C., Perry, S., Randle, K., Snowdon, C., Stobart, H., Wardley, A. M., Wheatley, D., Waters, S., Winter, M. C., Hubank, M., Allen, S. D., Bliss, J. M., Chan, S., Armstrong, A., Raja, F., Schmid, P., Tutt, A., Roux, R., & Cleator, S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2023-02
Volume
34
Issue
2
Pages
200-211
ISSN
0923-7534 (ISSN-L)
OpenAlex
W4309773737
Cited by
208
References
4
FWCI
13.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. https://app.cochat.ai/papers/10.1016/j.annonc.2022.11.005
The paper
Turner, N. C., Swift, C., Jenkins, B., Kilburn, L., Coakley, M., Beaney, M., Fox, L., Goddard, K., Garcia-Murillas, I., Proszek, P., Hall, P., Harper-Wynne, C., Hickish, T., Kernaghan, S., Macpherson, I. R., Okines, A. F. C., Palmieri, C., Perry, S., Randle, K., . . . Cleator, S. (2023). Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.11.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.